SGU Grad on Dr. Oz: New FDA-Approved Drug Limits Migraines

Shivang Joshi, MD/MPH SGU ’08, appeared on FOX’s “Dr. Oz” show on October 26 to explain how clinical trials of the drug Emgality—recently approved by the US Food and Drug Administration—have shown a drastic reduction of migraine frequency in patients. In one study, he explained that 1 in 7 patients with Emgality were migraine-free for a month, versus 1 in 16 for those using a placebo.

View the entire segment by visiting the Dr. Oz website.

Dr. Joshi came to SGU from St. John’s University College of Pharmacy and Allied Health Professions. He earned his Doctor of Medicine and Master of Public Health at SGU before going on to complete a neurology residency at Beth Israel Medical Center in New York. He then completed a fellowship in headache medicine at Brigham and Women’s Hospital’s John R. Graham Headache Center, while also serving as an instructor of neuroscience at Harvard Medical School.